ZA993975B - Combination therapy for musculoskeletal frailty. - Google Patents

Combination therapy for musculoskeletal frailty.

Info

Publication number
ZA993975B
ZA993975B ZA9903975A ZA993975A ZA993975B ZA 993975 B ZA993975 B ZA 993975B ZA 9903975 A ZA9903975 A ZA 9903975A ZA 993975 A ZA993975 A ZA 993975A ZA 993975 B ZA993975 B ZA 993975B
Authority
ZA
South Africa
Prior art keywords
combination therapy
musculoskeletal frailty
frailty
musculoskeletal
therapy
Prior art date
Application number
ZA9903975A
Other languages
English (en)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA993975B publication Critical patent/ZA993975B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9903975A 1998-06-16 1999-06-15 Combination therapy for musculoskeletal frailty. ZA993975B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
ZA993975B true ZA993975B (en) 2000-12-15

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9903975A ZA993975B (en) 1998-06-16 1999-06-15 Combination therapy for musculoskeletal frailty.

Country Status (30)

Country Link
EP (1) EP1087764A1 (sk)
JP (1) JP2002518326A (sk)
KR (1) KR20010052852A (sk)
CN (1) CN1301160A (sk)
AP (1) AP9901582A0 (sk)
AR (1) AR018869A1 (sk)
AU (1) AU4054799A (sk)
BG (1) BG105041A (sk)
BR (1) BR9911324A (sk)
CA (1) CA2335134A1 (sk)
CO (1) CO5070587A1 (sk)
EA (1) EA200001186A1 (sk)
GT (1) GT199900087A (sk)
HN (1) HN1999000097A (sk)
HR (1) HRP20000859A2 (sk)
HU (1) HUP0102505A3 (sk)
ID (1) ID27599A (sk)
IL (1) IL138630A0 (sk)
IS (1) IS5691A (sk)
MA (1) MA26652A1 (sk)
NO (1) NO20006312L (sk)
OA (1) OA11505A (sk)
PA (1) PA8475901A1 (sk)
PE (1) PE20000646A1 (sk)
PL (1) PL344981A1 (sk)
SK (1) SK18912000A3 (sk)
TN (1) TNSN99124A1 (sk)
TR (1) TR200003544T2 (sk)
WO (1) WO1999065486A1 (sk)
ZA (1) ZA993975B (sk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
ATE346159T1 (de) 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
AU2001276608A1 (en) 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
AR018869A1 (es) 2001-12-12
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
OA11505A (en) 2004-05-07
NO20006312D0 (no) 2000-12-12
ID27599A (id) 2001-04-12
HRP20000859A2 (en) 2001-04-30
HN1999000097A (es) 1999-11-03
AU4054799A (en) 2000-01-05
AP9901582A0 (en) 1999-06-30
TR200003544T2 (tr) 2001-04-20
SK18912000A3 (sk) 2001-10-08
PE20000646A1 (es) 2000-08-05
JP2002518326A (ja) 2002-06-25
HUP0102505A3 (en) 2002-12-28
BR9911324A (pt) 2001-04-03
GT199900087A (es) 2000-12-07
BG105041A (en) 2001-08-31
MA26652A1 (fr) 2004-12-20
WO1999065486A1 (en) 1999-12-23
TNSN99124A1 (fr) 2005-11-10
PA8475901A1 (es) 2000-05-24
CO5070587A1 (es) 2001-08-28
KR20010052852A (ko) 2001-06-25
EA200001186A1 (ru) 2001-06-25
PL344981A1 (en) 2001-11-19
NO20006312L (no) 2000-12-12
IS5691A (is) 2000-10-27
CA2335134A1 (en) 1999-12-23
EP1087764A1 (en) 2001-04-04
CN1301160A (zh) 2001-06-27

Similar Documents

Publication Publication Date Title
ZA987839B (en) Combination therapy.
GB9817118D0 (en) Pharmaceutical compounds
ZA200108000B (en) Cosmetic compounds.
EP1089751A4 (en) ADJUVANTE THERAPY
GB9817623D0 (en) Pharmaceutical compounds
ZA987843B (en) Combination therapy.
GB9804885D0 (en) Therapeutic combination
GB9810886D0 (en) Pharmaceutical compounds
TW524114U (en) Massager
GB9812038D0 (en) Therapeutic compound
ZA973209B (en) Therapeutic compounds.
GB9816556D0 (en) Therapy
ZA993975B (en) Combination therapy for musculoskeletal frailty.
ZA993973B (en) Therapeutic combinations for musculoskeletal frailty.
GB9823847D0 (en) Pharmaceutical compounds
GB9808665D0 (en) Therapeutic compounds
GB9823845D0 (en) Pharmaceutical compounds
GB9824897D0 (en) Therapeutic compounds
GB9817197D0 (en) Pharmaceutical compounds
TW404250U (en) Massage machine
GB9827865D0 (en) Medicament
GB9808667D0 (en) Therapeutic compounds
TW365168U (en) Massage machine
GB9806039D0 (en) Therapy
HK1032349A1 (en) Melanoma therapy.